Skip to main content

Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products Workshop Summary (2014) / Chapter Skim
Currently Skimming:

References
Pages 67-70

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 67...
... 2014. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
Read the entire page →
From page 68...
... 2014. A regulatory approach to uncertainty for the "real world." Presentation at the IOM workshop series on Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products, February 12 and May 12, White Oak, Maryland.
Read the entire page →
From page 69...
... 2012. Influence of medical journal press releases on the quality of associated newspaper coverage: retrospective cohort study.
Read the entire page →

Key Terms

  • iom workshop
  • white oak
  • workshop series
  • communicating uncertainty
  • clinical trials

  • prescription drug
  • accessed september
  • clinical trial
  • sclerosis approved
  • drug risk

  • drug discovery
  • depressive disorder
  • neurology annual
  • retrospective cohort
  • drug safety

  • national randomized
  • randomized trial
  • risk communication
  • supporting fda
  • trial evidence

  • controlled trials
  • evidence supporting
  • regulatory pathway
  • novel therapeutic
  • accelerated approval

  • risk evaluation
  • medical journal
  • intervention effect
  • communication advisory
  • fda approval


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.